Related Experiment Video

Updated: May 17, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

Weight Loss-Independent Mechanisms of Kidney Protection With Glucagon-Like Peptide 1 Receptor Agonists and

Allon N Friedman1, Ilyas Oultache2, Robert Hovey2

  • 1Division of Nephrology, School of Medicine, Indiana University, Indianapolis, Indiana.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|May 15, 2026
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists offer kidney protection beyond weight loss. This review explores evidence suggesting GLP-1

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used for obesity and related conditions.
  • Their benefits for kidney disease are often attributed primarily to weight loss.
  • Emerging data challenge the notion that weight loss is the sole driver of renal protection.

Purpose of the Study:

  • To present an alternative hypothesis on the kidney-protective effects of GLP-1 receptor agonists.
  • To evaluate the evidence supporting a mechanism independent of weight loss.
  • To discuss clinical implications and future research directions.

Main Methods:

  • Review of existing randomized controlled trials in humans.
  • Analysis of data from clinical studies on GLP-1 receptor agonists and kidney outcomes.
  • Synthesis of evidence to support or refute the weight-loss-independent hypothesis.

Main Results:

  • Human trial data provide limited support for weight loss as the primary driver of renal benefits.
  • Evidence suggests that GLP-1 receptor agonists may have direct renoprotective effects.
  • The magnitude of kidney protection may not correlate directly with the degree of weight reduction.

Conclusions:

  • The renoprotective benefits of GLP-1 receptor agonists may be largely independent of weight loss.
  • Further research is needed to elucidate the direct mechanisms of kidney protection.
  • Understanding these mechanisms could optimize therapeutic strategies for kidney disease in patients using GLP-1 receptor agonists.
Keywords:
GLP1chronic kidney diseaseglucagon-like peptide 1 receptor agonistsobesitysemaglutidetirzepatide

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...